Core Viewpoint - The approval of BRIMOCHOL™PF by the FDA represents a significant milestone for the company, enabling the commercialization of an innovative treatment for presbyopia, which is expected to accelerate the drug's market entry [1][2]. Group 1: FDA Approval and Clinical Trials - The company's partner, Tenpoint Therapeutics, received FDA approval for the commercialization of BRIMOCHOL™PF, a combination eye drop treatment for presbyopia [1]. - The approval followed successful completion of Phase 3 clinical trials, with the BRIOI study demonstrating the combination therapy's superiority over individual treatments [1]. - In the BRIOII study, BRIMOCHOL™PF met all primary endpoints for improving near vision, showing a statistically significant increase in binocular uncorrected near visual acuity (BUCNVA) by three lines or more, while maintaining binocular uncorrected distance visual acuity (BUCDVA) [1]. Group 2: Safety and Tolerability - The BRIMOCHOL™PF showed good tolerability during over 72,000 treatment days monitored in the BRIOII study, with no serious treatment-related adverse events reported [2]. - The incidence of eye redness as a side effect was low, with only 2.8% of participants in the BRIOII study reporting this compared to 10.7% in those receiving only carbachol [2]. Group 3: Commercial Strategy and Partnerships - The FDA approval serves as a strong catalyst for the company's commercialization strategy, as it has established a network of eight commercial partners across the Asia-Pacific region and the Middle East [2]. - The recognition from the FDA is expected to expedite the market entry of BRIMOCHOL™PF, marking an important global milestone for the company [2].
兆科眼科-B(06622.HK)：TENPOINT接获FDA在美国就BRIMOCHOL™PF发出的批准